Angiotensin II Receptor Blockers: A New Class of Antihypertensive Drugs

Archives of Family Medicine

Volumn 5, Issue 6, 1996, Pages 351-356

  Velasquez, Manuel T ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; BENZOTHIADIAZINE DERIVATIVE; BIPHENYL DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; IMIDAZOLE DERIVATIVE; IRBESARTAN; LOSARTAN; TETRAZOLE DERIVATIVE; THIAZIDE DIURETIC AGENT;

ANIMAL; BLOOD PRESSURE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; HYPERTENSION; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SPONTANEOUSLY HYPERTENSIVE RAT;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZOTHIADIAZINES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CLINICAL TRIALS; DIURETICS; ENALAPRIL; HUMANS; HYPERTENSION; IMIDAZOLES; LOSARTAN; MULTICENTER STUDIES; RATS; RATS, INBRED SHR; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; SODIUM CHLORIDE SYMPORTER INHIBITORS; TETRAZOLES;

EID: 0030160419     PISSN: 10633987     EISSN: None     Source Type: Journal    
DOI: 10.1001/archfami.5.6.351     Document Type: Review

References (60)

1. Sealy JE, Laragh JH. The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. New York, NY: Raven Press; 1990:1287-1317.
2. Skeggs LT, Dorer FE, Kahn JR, Lentz KE, Levine M. The biochemistry of the renin-angiotensin system and its role in hypertension. Am J Med. 1976; 60:737-748.
3. Kotchen TA, Guthrie JP Jr. Renin-angiotensin-aldosterone and hypertension. Endocr Rev. 1980; 1:78-99.
4. Ames RP, Borkowski AJ, Sicinski AM, Laragh JH. Prolonged infusion of angiotensin II and norepinephrine and blood pressure, electrolyte balance, and aldosterone and cortical secretion in normal man and in cirrhosis with ascites. J Clin Invest. 1965;44:1171-1186.
5. Lohmeier TE, Cowley AW Jr. Hypertensive and renal effects of chronic low level intrarenal angiotensin infusion in the dog. Circ Res. 1979; 44:154-160.
6. Brown, AJ, Casals-Stenzel J, Goddord S, Lever AF, Morton JJ. Comparison of fast and slow pressor effects of angiotensin II in the conscious rat. Am J Physiol. 1981;241:H381-H388.
7. Diz DI, Baer PG, Nasjletti A. Angiotensin II-induced hypertension in the rat. J Clin Invest. 1983;72:466-477.
8. Pals DT, Masucci FD, Denning GS, Sipos F, Fessier DC. Role of the pressor action of angiotensin II in experimental hypertension. Circ Res. 1971;29:673-681.
9. Miller ED, Samuels AI, Haber E, Barger AC. Inhibition of angiotensin conversion in experimental renovascular hypertension. Science. 1972; 177:1108-1109.
10. Gavras H, Brunner HR, Vaughan ED, Laragh JH. Angiotensin-sodium interaction in blood pressure maintenance of renal hypertensive and normotensive rats. Science. 1973;180:1369-1392.
11. Buhler FR, Laragh JH, Baer L, Vaughan ED Jr, Brunner HR. Propranolol inhibition of renin secretion: a specific approach to diagnosis and treatment of renin-dependent hypertensive disease. N Engl J Med. 1972;287:1209-1214.
12. Brunner HR, Laragh JH. Saralasin in human hypertension: the early experience. Kidney Int. 1979; 15(suppl 9):36-44.
13. Gavras H, Brunner HR, Turini GA, et al. Antihypertensive effect of the oral angiotensin-converting enzyme inhibitor SQ14225 in man. N Engl J Med. 1978;298:991-995.
14. Weber MA, Drayer JIM, Priest RT, Chen TJ. Participation of the renin system in treatment-resistant hypertension as measured by acute blockade of the angiotensin-converting enzyme. Am J Nephrol. 1982;2:6-11.
15. Chiu AT, Herblin WF, McCall DE, et al. Identification of angiotensin II receptor subtypes. Biochem Biophys Res Commun. 1989;165: 196-203.
16. Timmermans PBMWM, Benfield P, Chiu AT, Herblin WF, Wong PC, Smith RD. Angiotensin II receptors and functional correlates. Am J Hypertens. 1992;5(suppl):221S-235S.
17. 2) receptor-mediated changes in potassium currents in cultured neurons: role of intracellular calcium. FASEB J. 1992;6:A1012.
18. 2 receptor stimulates protein tyrosine phosphatase activity and mediates particulate guanylate cyclase. Biochem Biophys Res Commun. 1992;183:206-211.
19. Brunner HR, Laragh JH, Baer L, et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med. 1972;286:441-449.
20. Dzau V, Kopelman RJ, Barger AC, Slater EE, Haber E. Renin-specific antibody for study of cardiovascular homeostasis. Science. 1980;207:1901-1903.
21. Burton J, Cody RJ, Herd JA, Haber E. Specific inhibition of renin by an angiotensinogen analogue: studies in sodium depletion and renin-dependent hypertension. Proc Natl Acad Sci USA. 1980;77:5476-5479.
22. Zusman RM. Renin and non-renin-mediated antihypertensive actions of converting enzyme inhibitors. Kidney Int. 1984;969-983.
23. Okunishi H, Miyazaki M, Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens. 1984;2: 277-284.
24. Okamura T, Okunishi H, Ayajiki K, et al. Conversion of angiotensin I to angiotensin II in dog isolated renal artery: role of two different angiotensin II-generating enzymes. J Cardiovasc Pharmacol. 1990;15:353-359.
25. Urata H, Healy B, Stewart RW, Bumpus M, Husain A. Angiotensin II-forming pathways in normal and failing hearts. Circ Res. 1990;66:883-890.
26. 8-angiotensin II for understanding and treatment of high blood pressure. Lancet. 1973;2:1045-1048.
27. Streeten DHP, Anderson GH Jr, Freilberg JM, Dalakos TG. Use of an angiotensin II antagonist (saralasin) in the recognition of 'angiotensinogenic' hypertension. N Engl J Med. 1975;292:657-662.
28. Case DB, Wallace JM, Keim HJ, Sealey JE, Laragh JH. Usefulness and limitations of saralasin, a partial competitive agonist of angiotensin II, for evaluating sodium and renin factors in hypertensive patients. Am J Med. 1976;60:825-836.
29. Anderson GH, Streeten DHP, Dalakos TG. Pressor response to 1-sar-8-ala-angiotensin II (saralasin) in hypertensive subjects. Circ Res. 1977; 40:243-250.
30. Baer L, Parra-Carrillo JZ, Radichevich I, Williams GS. Detection of renovascular hypertension with angiotensin II blockade. Ann Intern Med. 1977;86:257-260.
31. Wilson HM, Wilson JP, Slaton PE, Foster JH, Liddle GW, Hollifield GW. Saralasin infusion in recognition of renovascular hypertension. Ann Intern Med. 1977;87:36-42.
32. Furukawa Y, Kishimoto S, Nishikawa K, inventors; Takeda Chemical Industries Ltd, assignee. Hypotensive imidazole derivatives. US patent 4340598. July 20, 1982.
33. Chiu AT, McCall DE, Price WA, et al. Nonpeptide angiotensin II receptor antagonists VII: cellular and biochemical pharmacology of DuP753, an orally active antihypertensive agent. J Pharmacol Exp Ther. 1990;252:771-781.
34. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists: studies with EXP 9270 and DuP 753. Hypertension. 1990;15: 823-834.
35. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II antagonists VIII: characterization of functional antagonism displayed DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther. 1990;252:719-725.
36. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II antagonists IX: antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther. 1990; 252:726-733.
37. Burnier M, Centeno G, Grouzmann E, Walker P, Waeber B, Brunner HR. In vitro effects of DuP 753; a nonpeptide angiotensin II receptor antagonist, on human platelets and rat vascular smooth muscle cells. Am J Hypertens. 1991;4: 438-443.
38. Smith RD, Chiu AT, Wong PC, Herblin WF, Timmermans PBMWM. Pharmacology of nonpeptide angiotensin II receptor antagonists. Annu Rev Pharmacol Toxicol. 1992;32:135-165.
39. Wong PC, Price WA, Chiu AT, et al. Hypotensive action of DUP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Hypertension. 1990;15:459-468.
40. Fenoy FJ, Milicic I, Smith RD, Wong PC, Timmermans PBMWM, Roman R. Effects of DuP 753 on renal function of normotensive and spontaneously hypertensive rats. Am J Hypertens. 1991; 4(suppl):321S-326S.
41. Bovee KC, Wong PC, Timmermans PBMWM, Thoolen MJMC. Effects of nonpeptide angiotensin II receptor antagonist DuP 753 on blood pressure and renal function in spontaneously hypertensive PH dogs. Am J Hypertens. 1991;4(suppl):327S-333S.
42. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II antagonists XI, pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther. 1990;252:211-217.
43. 1 receptor subtype. Br J Pharmacol. 1993;110:761-771.
44. Lee JY, Brune ME, Warner RB. Characterization of antihypertensive activity of ABBOTT-81988 a nonpeptide angiotensin II antagonist in the renal hypertensive rat. J Pharmacol Exp Ther. 1994; 268:427-433.
45. Lee JU, Warner RB, Brune ME, et al. Cardiovascular effects of orally administered ABBOTT-81988, an angiotensin II antagonist, in conscious spontaneously hypertensive rats. Am J Hypertens. 1994;7:975-983.
46. Christen Y, Waeber B, Nussberger J, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers: inhibition of pressor response to exogenous angiotensin I and II. Circulation. 1991;83: 1333-1342.
47. Goldberg MR, Tanaka W, Barchowsky A, et al. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension. 1993;21:704-713.
48. Sissmann J, Bouroudian M, Armagnac C, Donazollo Y, Latreille M, Panis R. Angiotensin II blockade in healthy volunteers: tolerability and impact on renin angiotensin system components of single and repeated doses of a new angiotensin II receptor antagonist SR 47436 (BMS 186295). J Hypertens. 1994;12(suppl 3):508.
49. Burnier M, Rutschmann B, Nussberger J, et al. Salt-dependent effects of an angiotensin II antagonist in healthy subjects. Hypertension. 1993; 22:339-347.
50. Nelson E, Arcuri K, Ikeda L, Snavely D, Sweet C. Efficacy and safety of losartan in patients with essential hypertension. Am J Hypertens. 1992; 5:19A.
51. Tsunoda K, Abe K, Hagino T, et al. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens. 1993;6:28-32.
52. Grossman E, Peleg E, Carroll J, Shamiss J, Rosenthal T. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. Am J Hypertens. 1994;7:1041-1044.
53. Goldberg MR, Bradstreet TE, McWilliams EJ, et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin aldosterone system in hypertensive patients. Hypertension. 1995;25:37-46.
54. Dahlöf B, Keller SE, Makris L, et al. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens. 1995;8:578-583.
55. Weber MA, Byyny RL, Pratt JH, et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med. 1995;155:405-411.
56. Soffer BA, Wright JT Jr, Pratt JH, Wiens B, Goldberg AI, Sweet CS. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension. 1995;26:112-117.
57. Shaw H, Snavely D, Shahnaz S. Safety and efficacy of losartan (DuP 753, MK-945) in hypertensive patients with renal impairment. J Am Soc Nephrol. 1994;5:567.
58. 1 receptor antagonist irbesartan in hypertension. Hypertension. 1995;25:22-29.
59. Lacourcière Y, Brunner H, Irwin R, et al. Effect of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens. 1994; 12:1387-1393.
60. Remuzzi A, Perico N, Amuchastegui CE, et al. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol. 1993;4:40-49.